KRAS Mutations in Pancreatic Cancer: What Patients Need to Know

```

🔬

Part of our Pillar Guide Clinical Trials for Pancreatic Cancer →

If you've received a pancreatic cancer diagnosis — or if you're supporting someone who has — you may have heard the word KRAS come up in conversation with your oncologist or during genetic testing. It's a small word that carries enormous weight in pancreatic cancer biology.

KRAS is the most commonly mutated gene in pancreatic cancer, present in more than nine out of ten cases. For most of the history of cancer research, a KRAS mutation was considered an irreversible driver of the disease with no targetable treatment. That understanding is now changing — quickly — and for patients and families navigating this diagnosis, it's important to understand both what KRAS means biologically and what it may mean for your treatment options.

What Is KRAS?

KRAS is a gene that carries the instructions for making a protein called KRAS, which acts like a molecular on/off switch inside cells. In a healthy cell, the KRAS protein turns on briefly to transmit growth signals, then turns off again — a tightly regulated process. When a mutation occurs in the KRAS gene, this switch gets stuck permanently in the "on" position, sending continuous signals that tell the cell to grow, divide, and survive without the normal checks and balances.

In pancreatic cancer, KRAS mutations are not just common — they are believed to be one of the earliest molecular events in the disease's development. Studies of pancreatic precancerous lesions called PanINs (pancreatic intraepithelial neoplasias) show that KRAS mutations appear even at the earliest detectable stages, long before invasive cancer develops.

How Does a KRAS Mutation Drive Cancer Growth?

When KRAS is stuck in the "on" position, it activates a cascade of downstream signalling pathways — chains of molecular events that ultimately tell the cell's nucleus to keep dividing. The two most important pathways in this context are:

• The RAF/MEK/ERK pathway: promotes cell proliferation and prevents programmed cell death (apoptosis)
• The PI3K/AKT/mTOR pathway: supports cell survival, metabolism, and growth

These pathways don't just cause unchecked growth — they also help tumour cells evade the immune system, resist chemotherapy, and adapt to their environment. This is part of why pancreatic cancers harbouring KRAS mutations have historically been so difficult to treat.

Not All KRAS Mutations Are the Same

This is one of the most clinically important things to understand about KRAS in pancreatic cancer: the mutation is not a single alteration but a family of related changes, each occurring at a specific location on the KRAS protein. The specific variant matters — both for how aggressively the cancer may behave and for which targeted treatments may apply.

Why Was KRAS Called "Undruggable"?

For nearly four decades after KRAS mutations were first identified in cancer, researchers considered the KRAS protein essentially impossible to target with a drug. The reason comes down to the protein's structure: KRAS has a very smooth surface with few deep pockets or grooves for a drug molecule to bind to — unlike many other cancer targets that have obvious binding sites. Additionally, KRAS binds to its activating molecule (GTP) with such high affinity that blocking this interaction seemed impractical.

Scientists tried indirect approaches — targeting the proteins downstream of KRAS, or blocking the pathways it activates — but these strategies generally failed in pancreatic cancer because tumour cells adapted quickly and found alternative routes to sustain growth.

The breakthrough came in 2013, when researchers at UC San Francisco identified a small pocket on the G12C variant of the KRAS protein that appeared only when the protein was in its inactive "off" state. This discovery led directly to the development of covalent KRAS G12C inhibitors — drugs that permanently lock KRAS in the off position — and eventually to the first approved KRAS-targeted therapies for lung cancer in 2021.

Where Does Treatment Stand Today?

The progress in KRAS-targeted therapy over the past five years has been substantial, though it is important to be clear-eyed about what is available now versus what is still in development for pancreatic cancer specifically.

Approved Therapies (as of 2026)

Sotorasib (Lumakras) and adagrasib (Krazati), both G12C inhibitors, are currently approved for non-small cell lung cancer harbouring KRAS G12C mutations. Because only 1–2% of pancreatic cancers carry G12C, these approved drugs apply to a very small subset of pancreatic cancer patients. Clinical trials are underway exploring these agents in pancreatic cancer — with and without combination partners — but results in pancreatic tumours have so far been more modest than in lung cancer.

In Development: G12D and G12V Inhibitors

Because G12D and G12V together account for roughly 75% of KRAS-mutated pancreatic cancers, these are the variants that researchers are most urgently working to target. Several promising candidates are currently in Phase I and Phase II trials:

• MRTX1133 — a G12D-specific inhibitor that has shown strong preclinical activity and is in early-phase human trials
• RMC-6236 (pan-RAS inhibitor) — targets multiple KRAS mutations including G12V; Phase I/II data in pancreatic cancer are being eagerly watched
• Combination strategies — pairing KRAS inhibitors with SHP2 inhibitors, MEK inhibitors, or immunotherapy agents, to prevent the adaptive resistance that has limited single-agent approaches

The Role of the Tumour Microenvironment

One reason KRAS inhibitors that work well in lung cancer have had more limited success in pancreatic cancer is the unique biology of pancreatic tumours. Pancreatic cancer creates a dense, fibrous environment around the tumour — called the tumour microenvironment or stroma — that acts as a physical barrier preventing drugs from penetrating effectively and shielding the cancer from immune attack. Many researchers believe that overcoming this barrier will require combination strategies that attack both the KRAS mutation and the surrounding tumour architecture.

Getting Tested: Do You Know Your KRAS Variant?

If you have been diagnosed with pancreatic cancer and have not yet had comprehensive molecular profiling of your tumour, this is one of the most important conversations to have with your oncologist. Knowing your specific KRAS variant — and whether your cancer has other actionable alterations alongside or instead of KRAS — is increasingly essential for accessing targeted therapy trials.

There are two main types of molecular testing relevant here:

• Somatic tumour profiling (NGS): analysis of the tumour tissue itself to identify the specific mutations driving that cancer — including which KRAS variant is present
• Germline genetic testing: a blood test to identify inherited mutations (such as BRCA1/2 or PALB2) that may be relevant to treatment and to family risk assessment

Tumour profiling can typically be done from a biopsy sample or, in some cases, from surgical specimens. Our Testing resource page provides more detail on these tests and how to ask for them.

Questions to Ask Your Oncologist About KRAS

• Has my tumour been tested for its specific KRAS variant? If not, can it be?
• Do I have a G12C, G12D, G12V, or other KRAS mutation — and does the specific variant affect my trial eligibility?
• Are there any active clinical trials targeting my specific KRAS variant that I might be eligible for?
• Am I a candidate for pan-RAS or multi-target combination trials, even if I don't have G12C?
• Should I also have germline testing done alongside somatic profiling?
• If my tumour is KRAS wild-type, what other mutations should be investigated?
• How quickly is the landscape changing, and when should we revisit this conversation?

Looking Ahead: Reasons for Cautious Hope

The science of KRAS-targeted therapy is moving faster now than at almost any previous point in oncology. The combination of improved structural understanding of the KRAS protein, novel drug chemistry, and increasingly sophisticated combination strategies means that treatments which were genuinely unavailable five years ago are now entering clinical trials — and some are already showing real signals of activity in pancreatic cancer.

It is important to be honest: we are not yet at a point where KRAS inhibitors are standard-of-care treatments for pancreatic cancer. The G12D and G12V variants that affect the vast majority of patients are still primarily addressed through experimental trials rather than approved drugs. Resistance remains a serious challenge. And pancreatic cancer's tumour microenvironment continues to complicate drug delivery in ways that researchers are actively working to solve.

But the trajectory has changed. "Undruggable" is no longer the word researchers use when they talk about KRAS. For patients with pancreatic cancer — a disease that has seen far too little progress for far too long — that shift in scientific vocabulary matters.

The Heather Cutler Foundation will continue to track developments in KRAS-targeted therapy and update our resources as the evidence evolves. Heather's story is one of barriers: barriers to trials, barriers to information, barriers to hope. Understanding what's happening at the molecular level of this disease is one of the most powerful tools we can give patients and families who deserve better than what the standard of care has historically offered.

Related Articles

This article is for educational purposes only and does not constitute medical advice. The landscape of KRAS-targeted therapy is evolving rapidly; information about specific drugs or trials may have changed since this article was last reviewed. Always discuss treatment decisions — including clinical trial participation — with your oncologist and care team. Trial eligibility criteria should be verified directly with the trial site.